Zentalis Pharma Stock (NASDAQ:ZNTL), Trade Ideas

Zentalis Pharma

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AMWL

DISH

IBRX

LILM

MLTX

OLMA

PLCE

SATS

SEDG

SPHR

SPWR

TGLS

ZNTL

U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.

TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday

Long Ideas

Insider Trades

Pre-Market Outlook

ASAN

JUVF

Although US stocks closed lower on Tuesday, there were a few notable insider trades.

Around $108M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Carvana

Biotech

Short Sellers

Short Ideas

Tech

General

CVNA

NKLA

VERV

5 Short Squeeze Stocks In Play Thursday: Nikola, Verve, Carvana, More

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharmaceuticals Inc

For the fourth quarter of fiscal 2024, the Company expects to report revenue in the range of $135 million to $145 million and earnings in the range of $0.00 to $0.10 per diluted share.
The revenue and earnings estimates for the third and fourth quarters of fiscal 2024, and the finalization of financial results for the third quarter of 2024, are subject to completion of the Company's quarterly close and review procedures which are still ongoing. The Company plans to report its complete results and host its earnings conference call for the third quarter of fiscal 2024 on May 7, 2024. Details for the conference call have been announced in a separate press release.

Guidance

KTCC

Key Tronic Corporation Sees Q4 2024 EPS $0.00-$0.10; Revenue $135M-$145M

Key Tronic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>), a provider of electronic manufacturing services (EMS), today announced its preliminary results for the three months ended March 30, 2024.
For the third quarter of fiscal 2024, Key Tronic expects to report revenue of approximately $140 million, in line with revenue expectations, and a net loss of approximately ($0.18) to ($0.23) per share, which is below expectations.
The lower than expected earnings are primarily a result of severance costs of approximately $3.7 million, or $0.27 per diluted share, as the Company reduced its workforce by over 450 employees in Mexico. Moreover, the severance costs were incurred late in the third quarter, which limited the previously planned payroll expense reductions anticipated in the third quarter. The workforce reduction reflects softening demand for a number of different programs with high labor content and is expected to save more than $10 million annually.
Key Tronic expects production levels from Mexico-based facilities to recover in coming quarters due to recently won programs. The Company does not anticipate needing to increase its net headcount in coming periods, which would reflect significant improvements to operating efficiencies.
During the third quarter of fiscal 2024, Key Tronic's facilities in Mississippi and Arkansas were also offline for approximately two weeks due to severe winter weather events, resulting in unanticipated lost production capacity incurring a loss of contribution margin of approximately $1 million or $0.07 per diluted share. The Company also continued to be adversely impacted by the strengthening of the Mexican Peso by approximately 5% , increasing expenses by approximately $1.5 million or $0.11 per diluted share.

Earnings

Key Tronic Corporation Announces Preliminary Q3 EPS $(0.18)-$(0.23); Revenue ~$140M; Says Lower Than Expected Earnings Are Primarily A Result Of Severance Costs Of ~$3.7M, Or $0.27 Per Diluted Share, As The Company Reduced Its Workforce By Over 450 Employees In Mexico

Snap Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NASDAQ">SNAP</a>) shares are trading higher after the company reported its first-quarter financial results after the bell Thursday. Here's a <a href="https://www.benzinga.com/pressreleases/24/04/b38443869/snap-inc-announces-first-quarter-2024-financial-results">look at the highlights.&nbsp;</a>
The Details:
Snap reported quarterly earnings of 3 cents per share, which beat the analyst consensus estimate of a loss of 5 cents per share. 
Quarterly sales clocked in at $1.195 billion, which beat the analyst consensus estimate of $1.12 billion by 6.74% and represents a 20.88% increase over sales of $988.608 million from the same period last year.
The company reported 422 million daily active users in the first quarter, an increase of 39 million, or 10%, year-over-year. Total time users spent watching Spotlight content increased more than 125% year-over-year.&nbsp;
Snap said the number of Snapchat+ subscribers more than tripled year-over-year, surpassing 9 million subscribers in the first quarter, and the number of small and medium-sized advertisers on Snapchat increased 85% year-over-year.
&#8220;The value we provide our community and advertising partners has translated into improved financial performance,&#8221; said Evan Spiegel, CEO of Snap. &#8220;Our large, growing, and hard-to-reach community, brand-safe environment, and full-funnel advertising solutions have made us an increasingly important partner for businesses of all sizes.&#8221;
Outlook:&nbsp;
Snap sees second-quarter revenues between $1.225 billion and $1.255 billion, versus the $1.14 billion analyst estimate.&nbsp;
"As we enter Q2, we anticipate continued growth of our global community, and as a result, our Q2 guidance is built on the assumption that DAU will be approximately 431 million in Q2. We are focused on executing against our roadmap to deliver improvements to our DR advertising platform to drive improved results for our advertising partners and accelerate topline growth," the company said.&nbsp;
Related News: <a href="https://www.benzinga.com/news/earnings/24/04/38441140/s-p-global-reports-q1-results-raises-revenue-guidance">S&amp;P Global Reports Q1 Results, Raises Revenue Guidance</a>
SNAP Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Snap shares are up 24.5% after-hours at $14.23 at the time of publication Thursday.
Image: Sergei Elagin from Shutterstock

SNAP

Snap Shares Soar On Better-Than-Expected Q1 Results, Daily Active User Growth, Q2 Revenue Guidance

KLAC

KLA Expects Q4 Total Revenues Of $2.50B +/- $125M (Est $2.417B), Adj EPS Of $6.07 +/- $0.60 (Est $5.68)

Getty Realty Reaffirms 2024 AFFO Guidance Range Of $2.29-$2.31

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $3.34 by 4.79 percent. This is a 43.44 percent increase over earnings of $2.44 per share from the same period last year. The company reported quarterly sales of $372.791 million which beat the analyst consensus estimate of $353.570 million by 5.44 percent. This is a 45.09 percent increase over sales of $256.944 million the same period last year.

Earnings Beats

KNSL

Kinsale Cap Gr Q1 2024 Adj EPS $3.50 Beats $3.34 Estimate, Sales $372.791M Beat $353.570M Estimate

ACCD

Accolade Sees Q1 Revenue $103M-$106M vs $110.86M Est., FY24 Revenue $480M-$500M vs $413.5M Est.

WIIM

EXPO

Exponent shares are trading higher after the company reported better-than-expected Q1 financial results.

Exponent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.47 by 25.53 percent. This is a 5.36 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $144.933 million which beat the analyst consensus estimate of $125.979 million by 15.05 percent. This is a 3.30 percent increase over sales of $140.309 million the same period last year.

Exponent Q1 2024 GAAP EPS $0.59 Beats $0.47 Estimate, Sales $144.933M Beat $125.979M Estimate

SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.74 by 16.22 percent. The company reported quarterly sales of $149.576 million which beat the analyst consensus estimate of $146.564 million by 2.05 percent. This is a 18.84 percent increase over sales of $125.868 million the same period last year.

SPSC

SPS Commerce Q1 2024 Adj EPS $0.86 Beats $0.74 Estimate, Sales $149.576M Beat $146.564M Estimate

COLM

Columbia Sportswear Sees FY24 EPS $3.65-$4.05 (Prior $3.45-$3.85) vs $3.66 Est.

Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024. &nbsp;
ASRS Annual Scientific Meeting Presentation Information
Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Date / Time: Wednesday, July 17th, 2024 at 8:45am CEST
Session: Wet AMD Symposium 1
Presenter: Charles C. Wykoff, MD, PhD, FASRS, Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital
The presentation will be available on the <a href="https://www.globenewswire.com/Tracker?data=Md0wK3ixbFirVUkNX_UXVHtl-WiK6ncsdmIXkH8HmDct5FVlF9KS2xblDKACpA7OS_FuPn0aT-cSZ6--6ReuZTpebTiUXK6ADdd8I_EGJPs5uiB0mt0937Q2IIIxx3Kc">News and Publications</a> section of Adverum's website shortly after the presentation.

ADVM

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

Robert Half Says 'Q2 Earnings Guidance, Led By Protiviti, Anticipates Higher Sequential Earnings For The First Time In Seven Quarters'

Business First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.57 by 12.28 percent. This is a 9.09 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $60.917 million which missed the analyst consensus estimate of $62.224 million by 2.10 percent. This is a 0.36 percent decrease over sales of $61.137 million the same period last year.

Earnings Misses

BFST

Business First Bancshares Q1 2024 Adj EPS $0.50 Misses $0.57 Estimate, Sales $60.917M Miss $62.224M Estimate

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.29) by 6.98 percent. The company reported quarterly sales of $210.118 million which beat the analyst consensus estimate of $169.703 million by 23.82 percent. This is a 4.66 percent decrease over sales of $220.382 million the same period last year.

PTCT

PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate

Carlisle shares are trading higher after the company reported better-than-expected Q1 financial results.

Comfort Systems shares are trading higher after the company reported better-than-expected Q1 financial results and increased its quarterly dividend.

Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.35 by 5.71 percent. This is a 27.59 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $125.575 million which missed the analyst consensus estimate of $127.744 million by 1.70 percent. This is a 18.24 percent decrease over sales of $153.597 million the same period last year.

SBCF

Seacoast Banking Q1 2024 Adj EPS $0.37 Beats $0.35 Estimate, Sales $125.575M Miss $127.744M Estimate

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.89 by 0.53 percent. The company reported quarterly sales of $789.000 million which beat the analyst consensus estimate of $772.298 million by 2.16 percent. This is a 6.48 percent increase over sales of $741.000 million the same period last year.

ALSN

Allison Transmission Q1 2024 GAAP EPS $1.90 Beats $1.89 Estimate, Sales $789.000M Beat $772.298M Estimate

Peoples Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIS#NASDAQ">PFIS</a>) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.65 by 15.38 percent. This is a 47.12 percent decrease over earnings of $1.04 per share from the same period last year.

PFIS

Peoples Financial Servs Q1 EPS $0.55 Misses $0.65 Estimate

Big Pharma patent cliffs seen fueling oncology M&A this year

Cantor Fitzgerald sees strong year ahead for oncology M&A

Cantor sees strong year ahead for oncology M&A

FLEX, OCUL and PRPL are among after hour movers

Zentalis Pharmaceuticals Inc (ZNTL) is around the top of the Healthcare sector according to InvestorsObserver.ZNTL received an overall rating of 41, which means that it scores higher than 41% of stocks. Additionally, Zentalis Pharmaceuticals Inc scored a 74 in the Healthcare sector, ranking it higher than 74% of stocks in

Will Zentalis Pharmaceuticals Inc (ZNTL) Stay at the Top of the Healthcare Sector?

PLAB, SMTC and WOOF are among after hour movers

The latest announcement is out from Zentalis Pharmaceuticals (ZNTL). Starting April 9, 2024, Zentalis Pharmaceuticals, Inc. will share a Corporate ...

Zentalis Pharmaceuticals to Present at Upcoming Conferences

Zentalis Pharmaceuticals (ZNTL) just unveiled an update. Melissa Epperly has stepped down as CFO and other key financial roles at Zentalis Pharmace...

Zentalis Pharmaceuticals Announces Executive Financial Transition

Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

ALXO

AMAM

ANAB

APLS

ARBK

ARVN

BCYC

CGON

CTMX

DAWN

DCPH

ENCP

ERAS

ESAC

EXEL

FLEX

FUSN

GERN

GLAXF

HARP

IDYA

IMCR

IMNM

IMTX

JANX

JRVR

KPTI

KURA

LEGN

LFMD

MRUS

NUVL

OCUL

ORIC

PLAB

PMVP

PRPL

RLAY

RVMD

SGMT

SMTC

SNDX

SWTX

URGN

VSTM

WOOF

XPDB

Press Releases

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Health Care

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024